RxDoctor Payments DataLook up a doctor →

Anup Patel, MD

Nephrology · West Orange, NJNPI 1942391842

Payments from drug & device makers

$1,027,962in general payments, 2019–2025

Across 588 payments — averaging $1748.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Merck$683K
  • CSL Behring$212K
  • Novartis$62K
  • Astellas Pharma Global Development$46K
  • Takeda Pharmaceuticals U.S.A., Inc.$12K
  • Veloxis Pharmaceuticals, Inc.$5K
  • plus $8K from 6 others

What the payments were for

  • Consulting fees$5,84324%
  • Speaking & faculty fees$17,39971%
  • Travel & lodging$8133%
  • Food & beverage$6082%

General payments by program year

19
20
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,027,962 in reported general payments places this provider in the 95th percentile of 413 nephrology providers in New Jersey.

See all nephrology providers in New Jersey

Medicare billing

Part B allowed, 2024
$165,236
Medicare patients
355
Services billed
1,239

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Cinacalcet Hcl73$57,292
Atovaquone52$29,013
LokelmaSodium Zirconium Cyclosilicate23$22,603
Valganciclovir Hcl52$19,348
EliquisApixaban24$18,647
VeltassaPatiromer Calcium Sorbitex13$15,492
Tacrolimus50$12,151
Mycophenolic AcidMycophenolate Sodium34$5,550
Famotidine324$2,655
Prednisone380$2,225
Nifedipine ErNifedipine58$2,135
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim251$1,824
Mycophenolate Mofetil16$1,521
Valsartan30$1,489
Hydralazine Hcl108$1,393

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma$17$22,60323 claims
PfizerEliquis$4,000$18,64724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 413 nephrology providers in New Jersey.

Other nephrology in West Orange

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →